Invention Grant
US08501918B2 Immobilized tumor necrosis factor-α muteins for enhancing immune response in mammals
有权
固定化的肿瘤坏死因子-α突变蛋白,用于增强哺乳动物的免疫反应
- Patent Title: Immobilized tumor necrosis factor-α muteins for enhancing immune response in mammals
- Patent Title (中): 固定化的肿瘤坏死因子-α突变蛋白,用于增强哺乳动物的免疫反应
-
Application No.: US12378078Application Date: 2009-02-11
-
Publication No.: US08501918B2Publication Date: 2013-08-06
- Inventor: Mark Douglas Howell
- Applicant: Mark Douglas Howell
- Applicant Address: US CO Boulder
- Assignee: Cytologic, Inc.
- Current Assignee: Cytologic, Inc.
- Current Assignee Address: US CO Boulder
- Agency: Patterson Thuente Pedersen, P.A.
- Main IPC: C07K14/525
- IPC: C07K14/525 ; C07K17/02 ; C07K17/12 ; C07K17/14 ; A61K35/14

Abstract:
The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNFα muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNFα mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.
Public/Granted literature
- US20090227750A1 Mehod for enhancing immune response in mammals Public/Granted day:2009-09-10
Information query